Related Experiment Videos
Ongoing clinical trials in systemic hypertension
1Speedel Group, Hirschgaesslein 11, 4051 Basel, Switzerland. jessica.mann@speedelgroup.com
Insights
Hypertension remains a public health challenge, with many diagnosed patients undertreated or failing to reach blood pressure goals. New antihypertensive drugs offer potential, but their impact on long-term outcomes requires further study.
Area of Science:
- Cardiology
- Public Health
- Pharmacology
Background:
- Hypertension is a significant cardiovascular risk factor, particularly in older adults.
- Despite available treatments, many diagnosed hypertension patients remain undertreated or do not achieve target blood pressure levels.
- The increasing number of antihypertensive medications necessitates evaluation of their real-world impact.
Purpose of the Study:
- To review the current landscape of hypertension treatment and management.
- To discuss the challenges in achieving target blood pressure in treated patients.
- To summarize ongoing and recent long-term morbidity and mortality trials comparing different antihypertensive drug classes.
Main Methods:
- Literature review of hypertension epidemiology and treatment guidelines.
- Analysis of trends in antihypertensive drug development and market availability.
- Overview of comparative effectiveness trials for various pharmacological approaches.
Main Results:
- A significant gap exists between diagnosed hypertension and adequately controlled blood pressure.
- Many patients require multiple antihypertensive drugs to reach therapeutic goals.
- Recent trials compare novel pharmacological classes against established treatments.
Conclusions:
- Effective hypertension management remains a critical public health goal.
- Further research is needed to assess the long-term benefits of new antihypertensive therapies.
- Comparative trials are essential for guiding optimal therapeutic strategies in hypertension.
Abstract:
Hypertension was identified as a cardiovascular risk factor in the late fifties and still remains a public health issue. The number of patients treated reaches only half of those diagnosed and, of those treated, half fail to reach target blood pressure. Furthermore, the number of antihypertensive drugs reaching the market has increased exponentially in the last few years, however, the impact on treatment and on attaining target blood pressure levels remains to be seen. The high percentage of treated patients who do not reach target blood pressure, combined with the high number of patients requiring more than one antihypertensive drug, have triggered a series of long-term morbidity and mortality trials comparing different therapeutic approaches ('new' pharmacological classes vs. 'old' pharmacological classes). These are described in this paper.